Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo subsidiary Plexxikon's oral small molecule PLX3397 joined the ranks of Amgen's trebananib and ganitumab as well as ganetespib from Synta Pharmaceuticals in the large, multi-arm, investigator-sponsored breast cancer clinical trial known as I-SPY 2.
You may also be interested in...
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.
Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen Faces Potential Lack Of Near-Commercial Assets
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
Need a specific report? 1000+ reports available
Buy Reports